Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 12/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SLC2A9 | Q9NRM0 | 2/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069750 | 0.90 | SLC22A12 (0.53) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL15605969 | 0.90 | SLC22A12 (0.53) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL15555930 | 0.89 | SLC22A12 (0.53) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL16297172 | 0.88 | SLC22A12 (0.52) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL15555009 | 0.87 | SLC22A12 (0.51) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL30487683 | 0.87 | SLC22A12 (0.51) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL20494962 | 0.87 | SLC22A12 (0.51) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL19867938 | 0.86 | SLC22A12 (0.48) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL15605855 | 0.86 | SLC22A12 (0.49) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL19847623 | 0.84 | SLC22A12 (0.48) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219902-A1 | PREPARATION METHOD FOR CHLORINATED COMPOUND | JIANGSU KANION PHARMACEUTICAL Co.,Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219902-A1 | PREPARATION METHOD FOR CHLORINATED COMPOUND | JIANGSU KANION PHARMACEUTICAL Co.,Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4166543-A1 | PREPARATION METHOD FOR CHLORINATED COMPOUND | Jiangsu Kanion Pharmaceutical Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-11352331-B2 | Crystal and salt of 4-(naphthalen-1-yl)-4H-1,2,4-triazole compound and preparation method therefor | MEDSHINE DISCOVERY (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20210078960-A1 | CRYSTAL AND SALT OF 4-(NAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOLE COMPOUND AND PREPARATION METHOD THEREFOR | JIANGSU KANION PHARMACEUTICAL CO.,LTD (CN) | 2021-03-18 | — | — | US | disclosed |
| EP-3725781-A1 | CRYSTAL AND SALT OF 4-(NAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOLE COMPOUND AND PREPARATION METHOD THEREFOR | Medshine Discovery Inc. (CN) | 2020-10-21 | — | — | EP | disclosed |
| US-10633351-B2 | Halogenated compound and axially chiral isomer thereof | MEDSHINE DISCOVERY INC. (CN) | 2020-04-28 | — | — | US | disclosed |
| EP-3281941-B1 | PROCESS FOR PREPARING 2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ZENTIVA KS (CZ) | 2019-07-24 | — | — | EP | disclosed |
| EP-3281941-B1 | PROCESS FOR PREPARING 2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ZENTIVA KS (CZ) | 2019-07-24 | — | — | EP | disclosed |
| US-10351537-B2 | Processes for the preparation of lesinurad and intermediates thereof | APOTEX INC. (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009070740-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219902-A1 | PREPARATION METHOD FOR CHLORINATED COMPOUND | DDT, CAT, CYP2D6 | SLC22A12 3882/4885CYP2C9 7/4885CYP2C19 6/4885 |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-11352331-B2 | Crystal and salt of 4-(naphthalen-1-yl)-4H-1,2,4-triazole compound and preparation method therefor | CYP27A1, GOT1, NOD1 | SLC22A12 136/4885CYP2C9 1717/4885CYP2C19 2270/4885 |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-10351537-B2 | Processes for the preparation of lesinurad and intermediates thereof | LSS, SQOR, PGD | SLC22A12 4221/4885CYP2C9 25/4885CYP2C19 55/4885 |
| US-20210078960-A1 | CRYSTAL AND SALT OF 4-(NAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOLE COMPOUND AND PREPARATION METHOD THEREFOR | CYP27A1, GOT1, NOD1 | SLC22A12 136/4885CYP2C9 1717/4885CYP2C19 2270/4885 |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-10633351-B2 | Halogenated compound and axially chiral isomer thereof | SLC10A1, SLC10A6, ABCG2 | SLC22A12 302/4885CYP2C9 134/4885CYP2C19 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.